Researchers Note Cautions About Geron Drug

This morning, an abstract containing new data on Geron?s drug imetelstat caused shares in the tiny, Menlo Park, Calif., biotechnology company to more than double to $7.78; they fell some, but still ended the day up 44% to $5.20, giving Geron a market capitalization of $670 million. Obviously, excitement around this medicine is high.